Phage therapy of E coli infections

A technology of Escherichia coli and bacteriophage, which is applied in the field of manufacturing, can solve the problem of pathogenic bacteria and other problems

Pending Publication Date: 2017-02-15
PHERECYDES PHARMA
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Emergence of resistance to the most powerful new antibiotics in these clinical E. coli strains, even during treatment, makes the battle against E. coli nosocomial pathogens extremely difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phage therapy of E coli infections
  • Phage therapy of E coli infections
  • Phage therapy of E coli infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0193] Example 1: Phage-host characteristics and kinetics

[0194] One-step growth experiments were performed as previously described to first determine productive lysis time, adsorption rate, and then phage release. To determine the rate of adsorption, samples were taken at different time intervals to analyze free phage particles in solution. For the determination of the productive time and the amount of phage released, E. coli bacteria were mixed with the phage solution and the phage were allowed to adsorb for 15 min. The mixture was immediately centrifuged at 5000 rpm for 10 min to remove free phage particles. The pellet was resuspended in 5 fresh LB medium and the culture was continued to incubate at 37°C. Samples were taken at 3 min intervals and phage titers determined. These results allowed calculation of the number of phage produced per bacterium (amount released), productive time and productive lytic effect (PLE), as shown in Table 3 below.

[0195] table 3

...

Embodiment 2

[0198] Example 2: Preparation of Mixed Compositions

[0199] The following mix compositions were constructed, each containing 10 -9 to 10 -11 Each phage between pfu:

[0200] Table 4

[0201] mixture Phage I BP953+BP1168 II BP953+BP1168+BP1229 III BP953+BP1151+BP1155+BP1176 IV BP700+BP953+BP970+BP1002+BP1176 V BP1002+BP1151+BP1155+BP1168+BP1176 VI BP539+BP700+BP753+BP814+BP1151+BP1176+BP1168

[0202] The following two other mixed compositions containing all the various phages covering the most important diversity of E. coli species were constructed.

[0203] Table 5A: Mix Composition A :

[0204]

[0205] Table 5B: Mix Composition B :

[0206]

Embodiment 3

[0207] Example 3: Bacterial susceptibility to the phage mixture of the invention

[0208] Use the phage mixture of the present invention to 2.10 9 A concentration of phage / ml was tested on various bacterial strains. Different bacterial concentrations were plated at a concentration of 2.10 9 phage / ml phage mixture and incubated at 37°C for 24h.

[0209] The mixture was tested on the different Escherichia coli bacteria listed in Table 2 as well as additional Escherichia coli bacteria including meningitis-causing bacteria from the R. Debré collection. coli bacteria (37 strains), BLSE (5 strains) and ST131 (9 strains) types of Escherichia coli bacteria, Escherichia coli bacteria from hospitalized patients (35 strains) and O157, Hemorrhagic Escherichia coli bacteria of type 0144 and 0104 (3 strains). The % of bacterial species susceptible to the mixture is listed in Table 6 below:

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia colis trains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Description

[0001] The present invention relates to novel phages, compositions comprising said phages, their manufacture and uses thereof. The invention is particularly useful in treating infections in mammals and improving the condition of a subject by modifying the flora in said subject. Background technique [0002] Phages are small viruses that exhibit the ability to infect and kill bacteria, while they do not affect cells from other organisms. Phages were first described by William Twort almost a century ago and independently discovered by Félix d'Herelle shortly thereafter, and more than 6000 different phages, including bacteria and archaeal viruses, have been discovered and morphologically described to date. Most of these viruses have a tail, while a few are polyhedral, filamentous or pleomorphic. They can be classified according to their morphology, genetic content (DNA or RNA), specific host, place of life (marine virus or other habitat) and life cycle. As intracellular parasit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76C07K14/005C12N7/00C12Q1/70G01N33/569A01N63/40
CPCC12N2795/10171C07K14/005C12N7/00G01N33/56916C12N2795/00021C12N2795/00022C12N2795/00032C12N2795/00071C12N2795/10121C12N2795/10122C12N2795/10131C12N2795/10132C12N2795/10221C12N2795/10222C12N2795/10231C12N2795/10232G01N2333/245C12N2795/00031C12N2795/10271G01N2800/52A61K35/76A61P31/04A01N63/40Y02A50/30A01N63/00C12Q1/18
Inventor 弗莱维雅·颇伊洛特海伦妮·布洛伊斯
Owner PHERECYDES PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap